Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
C-CAR088 in Relapsed or Refractory Multiple Myeloma
NCT03751293Phase 1Unknown
- Sponsor
- Lu Daopei Hospital
- Start
- Jan 2019
- Primary completion
- Oct 2019
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of trovocabtagene autoleucel in multiple myeloma (MM), sponsored by Lu Daopei Hospital. Primary endpoint: Incidence of treatment-emergent adverse events (TEAEs) at 30 days. Status: unknown.
02
Drugs
trovocabtagene autoleucel
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03751293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03751293.